Intravitreal vascular endothelial growth factor

详细信息    查看全文

• 作者：Thomas Bertelmann (1)
  Stephan Schulze (1)
  Reka B?l?ni (1)
  Walter Sekundo (1)
  Sebastian Irle (2)
  Thomas Stief (3)
  Stefan Mennel (4)
  
• 关键词：VEGF ; Stabilization ; Vitreous ; Vitrectomy ; Blood–retina barrier ; Vitreo ; retinal diseases
• 刊名：Graefe's Archive for Clinical and Experimental Ophthalmology
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：252
• 期：4
• 页码：583-588
• 全文大小：199 KB
• 参考文献：1. Ford KN, Saint-Geniez M, Walshe T, Zahr A, D’Amore PA (2011) Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 52:9478-487 CrossRef
  2. Kim LA, D’Amore PA (2012) A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 181:376-79 CrossRef
  3. Chen J, Smith LEH (2007) Retinopathy of prematurity. Angiogenesis 10:133-40 CrossRef
  4. Sato T, Kusaka S, Shimojo H, Fujikado T (2009) Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 116:2165-169 CrossRef
  5. Bressler SB (2009) Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 116(10 Suppl):S1–S7 CrossRef
  6. Oh IK, Kim SW, Oh J, Lee TS, Huh K (2010) Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res 35:1116-127 CrossRef
  7. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116:87-3 CrossRef
  8. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244:309-15 CrossRef
  9. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2010) Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 20:402-09
  10. Noma H, Funatsu H, Mimura T, Shimada K (2010) Visual acuity and foveal thickness after vitrectomy for macular edema. Ophthalmologica 224:367-73 CrossRef
  11. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327-33 CrossRef
  12. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M 3rd, Ferris FL (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388-398 CrossRef
  13. Bertelmann T, Spychalska M, Kohlberger L, Strodthoff S, Witteborn M, Kicova N, Sachs U, Irle S, Mennel S (2013) Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251(12):2697-704 CrossRef
  14. Bertelmann T, Mennel S, Sekundo W, Strodthoff S, Witteborn MC, Stief T, Nguyen N, Koss MJ (2013) Intravitreal functional plasminogen is elevated in central retinal vein occlusion. Ophthalmic Res 50(3):151-59 CrossRef
  15. Esser P, Heimann K, Bartz-Schmidt KU, Walter P, Krott R, Weller M (1997) Plasminogen in proliferative vitreoretinal disorders. Br J Ophthalmol 81:590-94 CrossRef
  16. Cunha-Vaz J, Bernardes R, Lobo C (2011) Blood–retinal barrier. Eur J Ophthalmol 21(Suppl 6):S3–S9
  17. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK (2008) Aqueous humor levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion. Eye (Lond) 22:42-8 CrossRef
  18. De Smet MD, Okada AA (2010) Cystoid macular edema in uveitis. Dev Ophthalmol 47:136-47 CrossRef
  19. Cornut PL, Francais-Maury C, Mauget-Faysse M (2008) Macular edema from various etiologies. J Fr Ophthalmol 31:225-33 CrossRef
  20. Rivera JC, Sapieha P, Joyal JS, Duhamel F, Shao Z, Sitaras N, Picard E, Zhou E, Lachapelle P, Chemtob S (2011) Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 100:343-53 CrossRef
  21. Stahl A, Lagreze WA, Agostini HAT (2012) Pathogenese der Frühgeborenenretinopathie. Ophthalmologe 109:1174-181 CrossRef
  22. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133:537-43 CrossRef
  23. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M (2002) Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 134:348-53 CrossRef
  24. Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Hori S (2005) Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112:806-16 CrossRef
  25. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 139:476-81 CrossRef
  26. Patel JI, Tombran-Tink J, Hykin PG, Gregor PH, Gregor ZJ, Vree IA (2006) Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res 82:798-06 CrossRef
  27. Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H (2008) Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 115:1916-922 CrossRef
  28. Noma H, Funatsu H, Mimura T, Shimada K (2010) Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion. J Inflamm 7:44 CrossRef
  29. Noma H, Funatsu H, Harino S, Mimura T, Eguchi S, Hori S (2011) Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol 55:248-55 CrossRef
  30. Stief TW (2008) Arginine conserves the hemostasis activation state of plasma even against freezing/thawing. In: Sch?fer HA, Wohlbier LM (eds) Diamino amino acids. Nova, New York, pp 219-33
  31. Loukovaara S, Robciuc A, Holopainen JM, Lehti K, Pessi T, Liinamaa J, Kukkonen KT, Jauhiainen M, Koli K, Keski-Oja J, Immonem I (2013) Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol 91(6):531-39. doi:10.1111/j.1755-3768.2012.02473.x CrossRef
  32. Clausen R, Weller M, Wiedemann P, Heimann K, Hilgers RD, Zilles K (1991) An immunochemical quantitative analysis of the protein pattern in physiologic and pathologic vitreous. Graefes Arch Clin Exp Ophthalmol 229(2):186-90 CrossRef
  33. Herold, G (2012) Innere Medizin, eine vorlesungsorientierte Darstellung, 2012: Spezieller Teil: Referenzbereichsliste. Herold, Munich, pp 930-37. ISBN: 978-3-9814660-1-0
  34. Kruithof EK, Ransijn A, Bachmann F (1982) Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators. Thromb Res 28(2):251-60 CrossRef
  35. Stief TW (2012) Thrombin—applied clinical biochemistry of the main factor of coagulation. In: Stief T (ed) Thrombin: function and pathophysiology. Nova, New York, pp vii–xx
  36. Koss MJ, Pfister M, Koch FH (2011) Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol 2011:459251. doi:10.1155/2011/459251 CrossRef
  37. Mantel I, Deli A, Iglesias K, Ambresin A (2013) Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251(3):697-04 CrossRef
  38. Muether PS, Hermann MM, Dr?ge K, Kirchhof B, Fauser S (2013) Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 156(5):989-93 CrossRef
  39. Muether PS, Neuhann I, Buhl C, Hermann MM, Kirchhof B, Fauser S (2013) Intraocular growth factors and cytokines in patients with dry and neovascular age-related macular degeneration. Retina 33(9):1809-814 CrossRef
  40. Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR (2009) Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 116(11):2158-164 CrossRef
  41. Ecker SM, Hines JC, Pfahler SM, Glaser BM (2011) Aqueous cytokine and growth factor levels do not reliably reflect those levels found in the vitreous. Mol Vis 17:2856-863
  42. Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R, Koch FH (2012) Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 90:e98–e103 CrossRef
  43. Muether PS, Droege KM, Fauser S (2013) Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab. Br J Ophthalmol 98(2):179-81
  44. Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S (2012) Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 119(10):2082-086 CrossRef
  
• 作者单位：Thomas Bertelmann (1)
  Stephan Schulze (1)
  Reka B?l?ni (1)
  Walter Sekundo (1)
  Sebastian Irle (2)
  Thomas Stief (3)
  Stefan Mennel (4)
  
  1. Department of Ophthalmology, Philipps-University Marburg, Baldingerstra?e, 35043, Marburg, Germany
  2. Freelance Collaborator, Marburg, Germany
  3. Department of Laboratory Medicine, Philipps-University Marburg, Marburg, Germany
  4. Department of Ophthalmology, Feldkirch Regional Hospital, Feldkirch, Austria
  
• ISSN：1435-702X

文摘

Purpose To evaluate whether a specific pre-analytical stabilization regimen is needed for na?ve vitreous taps to detect true values of intrinsic VEGF levels. Methods Fourteen consecutive patients with different vitreomacular pathologies without blood–retina-barrier breakdown were scheduled for standard 23-gauge three-port pars plana vitrectomy, and na?ve vitreous taps were sampled at the beginning of each procedure. The extracted vitreous specimen was split; one half was immediately stored in a ?0?°C freezer (unstabilized samples) and the other half was instantly stabilized with albumin (2.5?% final conc.), followed by arginine stabilization (1.25?M final conc.) and consecutively stored in a ?0?°C freezer (stabilized samples). Results Intravitreal VEGF was detected in all 14 analyzed samples (100?%). VEGF levels were shown to be 46.5?pg/ml?±-2.3?pg/ml (MV ± SD; range: 5.99-32.3?pg/ml) in unstabilized, and 120.4?pg/ml?±-4.4?pg/ml (range: 42.9?pg/ml-89.6?pg/ml) in stabilized vitreous samples. Intravitreal VEGF levels in stabilized vitreous samples were on average 2.6-fold, and thus significantly higher than in unstabilized taps of same eyes (p--.001, Wilcoxon test). VEGF levels in stabilized vitreous samples can be up to 8.5 times higher than in corresponding unstabilized vitreous taps of same eyes (bootstrap analysis). Intravitreal VEGF levels in unstabilized samples correlate with those in stabilized vitreous taps (r--.594; p--.025; Pearson). Conclusions An adequate pre-analytic stabilization regimen is needed to evaluate the most accurate intravitreal VEGF levels. This in turn will result in a better understanding of the physiological as well as pathological role of VEGF within the eye. Furthermore, knowing the true value of intravitreal VEGF levels will help to calculate the dosage of intravitrealy applied anti-VEGF drugs.